NCT06806683

Brief Summary

The ITHACA study aims to improve the treatment of head and neck cancer by developing a predictive tool that helps doctors personalize care for each patient. This tool uses information such as medical history, imaging, and radiotherapy data to predict the risk of cancer recurrence, overall survival, and the likelihood of side effects. Patients with head and neck cancer face significant challenges, including managing the side effects of treatments like radiotherapy. By tailoring treatment schedules and doses, and using advanced imaging techniques, we hope to reduce complications and improve survival outcomes. The study is designed to help doctors choose the best treatment for each patient, while minimizing the side effects that impact important functions like swallowing and breathing. Patients participating in the study will have their medical data collected, including: Tumor characteristics (size, location, stage). Treatment details (radiotherapy and chemotherapy). Imaging information using tools like PET-CT and MRI to track the response to treatment and detect any signs of cancer recurrence. Side effects and overall health data. This information will be used to develop and test a new model that predicts outcomes for each patient based on their unique data. The study includes adults (18 years and older) diagnosed with head and neck cancer, who are undergoing or have completed radiotherapy. Patients will be followed over time to monitor their response to treatment and any side effects.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
915

participants targeted

Target at P75+ for all trials

Timeline
165mo left

Started Jan 2023

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress20%
Jan 2023Dec 2039

Study Start

First participant enrolled

January 1, 2023

Completed
1.8 years until next milestone

First Submitted

Initial submission to the registry

October 21, 2024

Completed
4 months until next milestone

First Posted

Study publicly available on registry

February 4, 2025

Completed
9.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2034

Expected
4.9 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2039

Last Updated

February 4, 2025

Status Verified

October 1, 2024

Enrollment Period

12 years

First QC Date

October 21, 2024

Last Update Submit

January 31, 2025

Conditions

Keywords

Head and neck cancerRadiotherapyChemoradiotherapyRadiomicsPersonalized treatmentDosiomics

Outcome Measures

Primary Outcomes (1)

  • Cancer Recurrence

    The main focus is the probability of recurrence of head and neck cancer after the completion of radiotherapy. This will be assessed at various intervals, specifically at 3, 6, 12, 24, and 36 months post-treatment, using imaging techniques such as PET-CT, MRI, and CT, along with clinical evaluations.

    From enrollment to 36 months post-treatment

Interventions

intensity modulated radiotherapy

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

This study includes adult patients (≥18 years old) diagnosed with head and neck cancers. Patients are eligible if they are undergoing or scheduled to undergo radiotherapy or chemoradiotherapy in one of the following settings: definitive (primary treatment), adjuvant (post-surgical), or palliative (symptom relief or disease control). The study aims to evaluate treatment effectiveness and monitor side effects across a diverse patient cohort.

You may qualify if:

  • Participants must meet all of the following criteria:
  • Diagnosis: Confirmed head and neck cancer, including cancers of the oropharynx, larynx, hypopharynx, nasopharynx, salivary gland, unknown head and neck primary or oral cavity.
  • Age: 18 years or older.
  • Treatment: Undergoing or scheduled to undergo radiotherapy or chemoradiotherapy as part of their treatment

You may not qualify if:

  • Participants will be excluded if they meet any of the following criteria:
  • Pregnancy: Pregnant or breastfeeding women.
  • Non-Compliance: Patients unwilling or unable to comply with study procedures and follow-ups.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Rome, Lazio, 00168, Italy

Location

MeSH Terms

Conditions

Head and Neck NeoplasmsMouth NeoplasmsOropharyngeal Neoplasms

Interventions

Radiotherapy, Intensity-Modulated

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsMouth DiseasesStomatognathic DiseasesPharyngeal NeoplasmsOtorhinolaryngologic NeoplasmsPharyngeal DiseasesOtorhinolaryngologic Diseases

Intervention Hierarchy (Ancestors)

Radiotherapy, ConformalRadiotherapy, Computer-AssistedRadiotherapyTherapeutics

Study Officials

  • Mariangela Massaccesi, MD

    Fondazione Policlinico Universitario A. Gemelli, IRCCS

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
OTHER
Target Duration
5 Years
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 21, 2024

First Posted

February 4, 2025

Study Start

January 1, 2023

Primary Completion (Estimated)

December 31, 2034

Study Completion (Estimated)

December 1, 2039

Last Updated

February 4, 2025

Record last verified: 2024-10

Locations